small molecule

LYNPARZA

OLAPARIB

Loss of exclusivityOctober 2041latest FDA-listed patent expiry

CompanyASTRAZENECA PHARMACEUTICALS LP

Drug detail

Brand name	LYNPARZA
Active ingredient	OLAPARIB
Strength	100MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	August 2017
Marketing status	RX

Listed patents

Patent	Expires	Type
11970530	October 2041	use U-3931
8859562	August 2031	use U-3333
8475842	December 2029	product
11975001	October 2029	product
11633396	October 2029	product
12048695	October 2029	product
12178816	October 2029	product
12144810	October 2029	product
7449464	September 2027	substance, product
8071579	August 2027	use U-3333
8143241	August 2027	use U-3333

Regulatory exclusivity

Code	Expires
ODE-306	May 2027
ODE-283	December 2026
I-914	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ASTRAZENECA PHARMACEUTICALS LP